Novartis AG is a Swiss multinational pharmaceutical corporation formed in 1996 from the merger of Ciba-Geigy and Sandoz. The timeline traces its precursor companies' innovations, key leadership decisions, major drug approvals, acquisitions, and financial milestones, highlighting its evolution into one of the world's largest healthcare companies.
Johann Rudolf Geigy-Gemuseus founds a trading company in Basel, the origin of the Geigy family business.
Alfred Kern and Édouard Sandoz found Sandoz in Basel as a chemical company producing dyes.
The society of chemical industry Basel (Ciba) is established as a dyestuff manufacturer.
Geigy expands into pharmaceuticals, developing antiseptics and other drugs.
Ciba markets Antipyrine, an early synthetic antipyretic and analgesic, solidifying its presence in pharmaceuticals.
Sandoz launches Calcium-Sandoz (calcium gluconate), a widely used calcium supplement, marking its entry into pharmaceuticals.
Ciba develops Doriden (glutethimide), a sedative used in the mid-20th century.
Geigy scientists synthesize DDT; Paul Hermann Müller later wins Nobel Prize for its insecticidal properties.
Albert Hofmann at Sandoz synthesizes LSD, later discovering its psychedelic effects.
Geigy introduces Tofranil (imipramine), the first tricyclic antidepressant, revolutionizing depression treatment.
Sandoz begins developing ciclosporin (Sandimmune), an immunosuppressant later crucial for organ transplants.
Ciba and J.R. Geigy merge to form Ciba-Geigy, creating a major chemical and pharmaceutical company.
Ciba-Geigy introduces Voltaren (diclofenac), a nonsteroidal anti-inflammatory drug (NSAID) that becomes a blockbuster.
Sandoz introduces Sandostatin (octreotide), a synthetic analogue of somatostatin used for acromegaly and neuroendocrine tumors.
Ciba-Geigy markets Tegretol (carbamazepine), an anticonvulsant and mood stabilizer for epilepsy and bipolar disorder.
Sandoz receives FDA approval for Sandimmune (ciclosporin), transforming organ transplant success rates.
Ciba-Geigy introduces Habitrol (nicotine patch) for smoking cessation, a leading product in nicotine replacement therapy.
Sandoz introduces Clozaril (clozapine), an atypical antipsychotic effective for treatment-resistant schizophrenia.
Ciba-Geigy launches Lamisil (terbinafine), an antifungal medication that becomes a top seller.
Sandoz spins off its specialty chemicals division into Clariant, focusing on pharmaceuticals.
Ciba-Geigy and Sandoz merge to form Novartis AG, one of the largest pharmaceutical companies at the time.
Novartis launches Diovan (valsartan), an angiotensin II receptor blocker for hypertension, which becomes a blockbuster.
Novartis receives FDA approval for Gleevec (imatinib), a targeted therapy for chronic myeloid leukemia, revolutionizing cancer treatment.
Novartis acquires a majority stake in Chiron Corporation, a biopharmaceutical and vaccine company, expanding its vaccine and diagnostics portfolio.
Novartis launches Zometa (zoledronic acid), a bisphosphonate for bone metastases and osteoporosis.
Novartis launches Femara (letrozole), an aromatase inhibitor for breast cancer, becoming a leading therapy.
Novartis acquires Eon Labs, a generic drug manufacturer, to strengthen its generics division (Sandoz).
Novartis launches Aclasta/Reclast (zoledronic acid once-yearly) for osteoporosis, enhancing patient convenience.
Novartis sells its Gerber baby food and other nutrition businesses to Nestlé, focusing on pharmaceuticals.
Novartis acquires a majority stake in Alcon, the global leader in eye care, for approximately $39 billion.
Novartis launches Ilaris (canakinumab), an interleukin-1 beta inhibitor for autoinflammatory diseases.
Novartis launches Gilenya (fingolimod), the first oral disease-modifying therapy for multiple sclerosis. #pharmaceuticals #multiple sclerosis
Novartis launches Jakavi (ruxolitinib), a JAK inhibitor for myelofibrosis and polycythemia vera.
Novartis acquires GSK's oncology portfolio for $16 billion, strengthening its cancer drug pipeline.
Novartis launches Entresto (sacubitril/valsartan), a heart failure drug that shows significant mortality reduction.
Novartis launches Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, ankylosing spondylitis, and psoriatic arthritis.
Novartis launches Kisqali (ribociclib), a CDK4/6 inhibitor for advanced breast cancer.
Novartis partners with Amgen to launch Aimovig (erenumab), a CGRP antagonist for migraine prevention.
Novartis spins off Alcon as an independent publicly traded company, focusing on core pharmaceuticals.
Novartis receives FDA approval for Zolgensma, a gene therapy for spinal muscular atrophy (SMA), one of the most expensive drugs at $2.1 million per dose.
Novartis launches Scemblix (asciminib), a novel STAMP inhibitor for chronic myeloid leukemia.
Novartis announces plans to spin off its generics division Sandoz into a standalone company to focus on innovative medicines.
Novartis finalizes the spin-off of Sandoz, creating an independent generics and biosimilars company.
Novartis expands its radiopharmaceutical pipeline with Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive metastatic castration-resistant prostate cancer. )_vipivotide_tetraxetan
